Search results
Author(s):
Felipe Martínez
Added:
4 years ago
In this video, Prof Felipe Martinez, Professor of Medicine (Córdoba National University, Córdoba, AR) discusses the design and rationale for DAPA-HF.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is…
View more
Author(s):
Felipe Martínez
Added:
4 years ago
In this video, Prof Felipe Martinez, Professor of Medicine (Córdoba National University, Córdoba, AR) discusses the design and rationale for DAPA-HF.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more
Author(s):
Marc P Bonaca
,
Roxana Mehran
Added:
4 years ago
Dr Marc P Bonaca (University of Colorado, Aurora, US) and Prof Roxana Mehran (Mount Sinai Hospital, New York, US) provide a comprehensive review of clinical data on antithrombotics, with focus on ISCHEMIA, TWILIGHT, TWILIGHT-ACS and GALILEO.
TRIAL DISCUSSION TIMINGS
0:45s - ISCHEMIA
7:45s - TWILIGHT
9:50s - TWILIGHT-ACS
12:30s - GALILEO
Videographer: Tom Green and Dominic Woodruff.
Filmed…
View more
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Author(s):
Ajay J Kirtane
Added:
6 years ago
In this video Dr Ajay Kirtane discusses the way in which DEFINE-FLAIR has affected his clinical practice.
View more
Author(s):
Andrew JS Coats
,
Mikhail Kosiborod
Added:
1 year ago
This video series is dedicated to the adoption of patient-reported outcomes (PROs) and initiation of guideline-directed medical therapy (GDMT) in daily practice.
In this first discussion,Prof Andrew Coats (Heart Research Institute, Sydney, AU) and Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, US) address how to optimise clinical success using foundational…
View more
Author(s):
Harriette Van Spall
,
John Spertus
Added:
2 years ago
Late-breaker host Dr Harriette Van Spall (McMaster University, CA) invites PI, Dr John Spertus to discuss the innovative CHIEF-HF clinical trial.
The aim of this study was to determine the superiority of the effectiveness of canagliflozin versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score …
View more
Author(s):
Ersilia M DeFilippis
,
Yasbanoo Moayedi
,
Nosheen Reza
Added:
2 years ago
Author(s):
Harriette Van Spall
,
Mandeep Mehra
Added:
4 months ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were…
View more